Upgrade to SI Premium - Free Trial

Oncolytics Biotech (ONCY)

0.85 +0.02 (2.41%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/10/26 *Est.)

Latest Headlines

Form 8-K ONCOLYTICS BIOTECH INC For: Jul 20 July 20, 2026 9:03 AM - SEC Filing FDA grants fast track status to Oncolytics' pelareorep for anal cancer July 20, 2026 9:01 AM - StreetInsider Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer July 20, 2026 9:00 AM - Globe NewsWire H.C. Wainwright Reiterates Buy Rating on Oncolytics Biotech (ONCY) July 14, 2026 7:00 AM - StreetInsider Form 8-K ONCOLYTICS BIOTECH INC For: Jul 13 July 13, 2026 9:04 AM - SEC Filing Oncolytics to meet FDA on registrational path for REO 033 trial July 13, 2026 9:01 AM - StreetInsider Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial July 13, 2026 9:00 AM - Globe NewsWire Form 8-K ONCOLYTICS BIOTECH INC For: Jul 06 July 8, 2026 4:23 PM - SEC Filing Form 8-K ONCOLYTICS BIOTECH INC For: Jun 16 June 16, 2026 9:05 AM - SEC Filing ONCY secures U.S. patent for pelareorep manufacturing through 2044 June 16, 2026 9:00 AM - StreetInsider Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044 June 16, 2026 9:00 AM - Globe NewsWire Form 4 ONCOLYTICS BIOTECH INC For: Jun 01 Filed by: Pisano Wayne June 3, 2026 4:32 PM - SEC Filing Form 3 ONCOLYTICS BIOTECH INC For: Jun 01 Filed by: McAdory John Bearden June 3, 2026 4:32 PM - SEC Filing Form 4 ONCOLYTICS BIOTECH INC For: Jun 01 Filed by: RIGBY JONATHAN June 3, 2026 4:32 PM - SEC Filing Form 4 ONCOLYTICS BIOTECH INC For: Jun 01 Filed by: Look Kirk June 3, 2026 4:32 PM - SEC Filing Form 4 ONCOLYTICS BIOTECH INC For: Jun 01 Filed by: Holtham Angela June 3, 2026 4:32 PM - SEC Filing Form 4 ONCOLYTICS BIOTECH INC For: Jun 01 Filed by: Parsons James T. June 3, 2026 4:32 PM - SEC Filing Form 4 ONCOLYTICS BIOTECH INC For: Jun 01 Filed by: Aromando Andrew June 3, 2026 4:31 PM - SEC Filing Form 4 ONCOLYTICS BIOTECH INC For: Jun 01 Filed by: Kelly Jared June 3, 2026 4:31 PM - SEC Filing Form 3 ONCOLYTICS BIOTECH INC For: Jun 01 Filed by: Glover Stephen C. June 3, 2026 4:31 PM - SEC Filing Form 4 ONCOLYTICS BIOTECH INC For: Jun 01 Filed by: Andrews Patricia S June 3, 2026 4:31 PM - SEC Filing Form 4 ONCOLYTICS BIOTECH INC For: Jun 01 Filed by: Seizinger Bernd R. June 3, 2026 4:31 PM - SEC Filing Form 4 ONCOLYTICS BIOTECH INC For: Jun 01 Filed by: Hagerman Allison June 3, 2026 4:31 PM - SEC Filing Form 4 ONCOLYTICS BIOTECH INC For: Jun 01 Filed by: Brown Deborah Margaret June 3, 2026 4:30 PM - SEC Filing Form 4 ONCOLYTICS BIOTECH INC For: Jun 01 Filed by: Heineman Thomas Charles June 3, 2026 4:30 PM - SEC Filing Form 4 ONCOLYTICS BIOTECH INC For: Jun 01 Filed by: Glover Stephen C. June 3, 2026 4:30 PM - SEC Filing Form 4 ONCOLYTICS BIOTECH INC For: Jun 01 Filed by: McAdory John Bearden June 3, 2026 4:30 PM - SEC Filing Form 8-K ONCOLYTICS BIOTECH INC For: Jun 02 June 2, 2026 9:03 AM - SEC Filing Oncolytics Biotech adds Steve Glover to board, promotes John McAdory to COO June 2, 2026 9:00 AM - StreetInsider Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer June 2, 2026 9:00 AM - Globe NewsWire Form 8-K ONCOLYTICS BIOTECH INC For: Jun 01 June 1, 2026 9:06 AM - SEC Filing Oncolytics reports positive preclinical data for pelareorep-RAS combo June 1, 2026 9:03 AM - StreetInsider Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches June 1, 2026 9:00 AM - Globe NewsWire H.C. Wainwright Reiterates Buy Rating on Oncolytics Biotech (ONCY) May 26, 2026 6:59 AM - StreetInsider Form 8-K ONCOLYTICS BIOTECH INC For: May 22 May 22, 2026 9:03 AM - SEC Filing Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors May 22, 2026 9:00 AM - Globe NewsWire Form 10-Q ONCOLYTICS BIOTECH INC For: Mar 31 May 14, 2026 4:30 PM - SEC Filing "Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies May 14, 2026 11:12 AM - StreetInsider "Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies May 14, 2026 10:55 AM - Globe NewsWire Form 8-K ONCOLYTICS BIOTECH INC For: May 04 May 4, 2026 9:04 AM - SEC Filing Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer May 4, 2026 9:00 AM - Globe NewsWire Form 8-K ONCOLYTICS BIOTECH INC For: Apr 27 April 27, 2026 8:17 AM - SEC Filing Oncolytics receives FDA alignment on pivotal anal cancer study design April 27, 2026 8:10 AM - StreetInsider Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study April 27, 2026 8:10 AM - Globe NewsWire Full Article List